Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Malignant Solid Neoplasm 1Kidney Neoplasms 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × Ferrosoferric Oxide × Clear all
NCT02141490 2019-09-06

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms

NCT01296139 2018-07-05

Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡